Premium
Deferasirox ( ICL670A ) effectively inhibits oesophageal cancer growth in vitro and in vivo
Author(s) -
Ford SJ,
Obeidy P,
Lovejoy DB,
Bedford M,
Nichols L,
Chadwick C,
Tucker O,
Lui GYL,
Kalinowski DS,
Jansson PJ,
Iqbal TH,
Alderson D,
Richardson DR,
Tselepis C
Publication year - 2013
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.12045
Subject(s) - deferasirox , deferoxamine , cancer research , in vivo , cell growth , pharmacology , cancer , cisplatin , medicine , viability assay , in vitro , chemistry , biology , biochemistry , chemotherapy , microbiology and biotechnology , thalassemia
Growing evidence implicates iron in the aetiology of gastrointestinal cancer. Furthermore, studies demonstrate that iron chelators possess potent anti-tumour activity, although whether iron chelators show activity against oesophageal cancer is not known.